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Many early generation HIV vaccines or pre-exposure prophylaxis (PrEP) candidates will probably 
only offer modest reductions in susceptibility to infection, even when an individual adheres perfectly 
to the specified booster schedule or guidelines for use. Given the complexities of human behavior 
and interactions within communities, a marginal PrEP or vaccine efficacy at the individual level can 
have unexpected consequences in HIV interventions at the community level. To optimize the design 
of community-level trials for testing HIV prevention approaches, Dr. Dobromir Dimitrov (Vaccine and 
Infectious Disease Division, Fred Hutchinson Cancer Research Center) mathematically modeled the 
population effectiveness of two different approaches for reducing the rate of HIV transmission. He 
did so in collaboration with Dr. Benoît Mâsse (CHU Sainte-Justine Research Centre, University of 
Montreal) and Dr. Marie-Claude Boily (Department of Infectious Disease Epidemiology, Imperial 
College London). In addition to highlighting the likely public health impacts of two simulated 
interventions, their results point to specific ways of improving the design of clinical trials for testing 
HIV prophylaxis drugs, which are just starting to be approved by the U.S. Food and Drug 
Administration (e.g., Truvada®). 
A drug company seeking licensure for a prophylaxis candidate or vaccine needs only to show that 
the product is statistically superior, even marginally so, to a matched placebo in a small number of 
individual-based clinical trials, often only one or two. In essence, this simply requires the company to 
demonstrate that the lower bound of the 95% confidence interval around the estimated efficacy is 
greater than 0%. However, a product with an efficacy that is low but statistically significant can 
actually have a negative impact on the HIV epidemic at the community level (Boily et al., 2008). This 
can result from imperfect adherence to an intervention regimen, or from an increase in risky sexual 
behavior due to higher-than-actual perceived efficacy. To offset such effects, epidemiologists will 
often only consider a clinical trial to be successful if the results surpass a minimum individual-level 
efficacy (MIE) set substantially higher than 0% (Boily et al., 2008). The tradeoff is that, as 
researchers nudge the MIE set-point higher and higher, the size of the trial grows exponentially in 
terms of the number of participants needed and cost. 
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Dimitrov et al. adapted their modeling approach from an earlier simulation study of the effects of 
antiretroviral-based vaginal microbicides (VBM) in developing countries (Dimitrov et al., 2010). In the 
more recent modeling study, the authors investigated how the precision of the efficacy estimate 
obtained in clinical trials with different MIE set-points affects the projected public-health impact of 
antiretroviral-based oral PrEP and VBM. They did so under a variety of model conditions, including: 
intervention scenarios differing in degree of population coverage, rate at which antiretroviral 
resistance develops and level of adherence; varying levels of actual product efficacy; and either uni- 
or bi-directional protection. Uni-directional interventions were assumed to reduce only the user’s 
susceptibility to HIV, whereas bi-directional interventions were assumed to reduce the user's 
infectiousness as well as susceptibility. For each set of conditions, parameter values were sampled 
10,000 times from researcher-defined intervals of interest, or from empirically-based distributions 
representative of sub-Saharan Africa. This yielded outcome distributions for the authors' main public 
health endpoint, fraction of HIV infections prevented over ten years (see figure). 
In their simulations, Dimitrov et al. found that both PrEP and VBM were almost always beneficial 
across scenarios and parameter values. Overall, PrEP had a larger positive impact on the HIV 
epidemic than VBM, consistent with the latter intervention being used by women only and being 
restricted to a single route of transmission. Increasing the MIE set-point improved the precision of 
the public health endpoint for both interventions across all model conditions. This was expected, 
since a higher MIE requires the enrollment of more trial participants to achieve the same statistical 
power for a more stringent null hypothesis. Not surprisingly, a larger MIE also reduced the likelihood 
of interventions with a negative impact on the epidemic (red ovals in the figure). Despite these 
important effects of the MIE set-point on trial outcomes, the authors found that implementation 
factors and characteristics of the target communities (i.e., the different intervention scenarios) were 
the most important drivers of uncertainty in predicting public health outcomes. 
In light of the limitations in funding available for clinical trials of HIV intervention strategies, the 
findings of Dimitrov et al. have very significant implications. Often, the geometric increase in trial cost 
is not justified by the moderate improvement in endpoint precision that accompanies a linear 
increase in MIE. The authors recommend that funds may be better spent, in some cases, on a 
greater number of moderate-sized clinical trials. This would allow epidemiologists to investigate a 
greater diversity of intervention strategies while being more thorough about evaluating critical 
implementation factors and population characteristics during each trial. 
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Adapted from the manuscript 
Modeled effects of oral pre-exposure prophylaxis (PrEP) on the 
cumulative fraction of HIV infections prevented over a ten year 
period (y-axes) under four intervention scenarios (x-axes). 
Observed 'actual' efficacies were set to 33% and 50% for the top 
and bottom plots, respectively. For each scenario, distribution 
ranges are given (below the plots) for three parameters: 
coverage (% individuals in the population receiving PrEP); 
resistance (annual rate at which antiretroviral drug resistance 
develops); and adherence (relative PrEP efficacy under imperfect 
adherence by an individual). In every scenario, the minimum 
desired individual-level efficacy (MIE) was set to 0%, 10% or 
20%, as indicated by the color-coded keys. Red ovals highlight 
portions of the outcome distributions where the PrEP intervention 
scenario actually poses a slight risk of negative impact on the 
HIV epidemic. 
